CLASS ACTION UPDATE for COG, RCL and MESO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Back to Newsroom
Mentioned in this Article

CLASS ACTION UPDATE for COG, RCL and MESO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Monday, October 12, 2020 6:20 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / October 12, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

COG Shareholders Click Here: https://www.zlk.com/pslra-1/cabot-oil-gas-corporation-information-request-form?prid=10005&wire=1
RCL Shareholders Click Here: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10005&wire=1
MESO Shareholders Click Here: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10005&wire=1

* ADDITIONAL INFORMATION BELOW *

Cabot Oil & Gas Corporation (NYSE:COG)

COG Lawsuit on behalf of: investors who purchased October 23, 2015 - June 12, 2020
Lead Plaintiff Deadline : October 13, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cabot-oil-gas-corporation-information-request-form?prid=10005&wire=1

According to the filed complaint, during the class period, Cabot Oil & Gas Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Cabot had inadequate environmental controls and procedures and/or failed to properly mitigate known issues related to those controls and procedures; (ii) as a result, Cabot, among other issues, failed to fix faulty gas wells, thereby polluting Pennsylvania's water supplies through stray gas migration; (iii) the foregoing was foreseeably likely to subject Cabot to increased governmental scrutiny and enforcement, as well as increased reputational and financial harm; (iv) Cabot continually downplayed its potential civil and/or criminal liabilities with respect to such environmental matters; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Royal Caribbean Cruises Ltd. (NYSE:RCL)

RCL Lawsuit on behalf of: investors who purchased February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10005&wire=1

According to the filed complaint, during the class period, Royal Caribbean Cruises Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.

Mesoblast Limited (NASDAQ:MESO)

MESO Lawsuit on behalf of: investors who purchased April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10005&wire=1

According to the filed complaint, during the class period, Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: